IP Library Granted Patent US 8,716,033
Granted Patent B2
US 8,716,033 · App. 11/674,136 · Granted May 6, 2014

Oligosaccharide modification and labeling of proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,716,033
App. No.
11/674,136
Granted
May 6, 2014
Kind
B2
Abstract

The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.

Claims (15)

1. A method of producing a glycomodified protein, comprising

attaching an azido-modified galactose to a GlcNAc residue on a first protein having a GlcNAc-GlcNAc linkage; and

mixing said first protein, having attached thereto said azido-modified galactose with a reporter molecule, carrier molecule or solid support capable of reacting with the azide group of said azido-modified galactose;

wherein said azido-modified galactose is N-azidoacetylgalactosamine (GalNAz) and said reporter molecule, carrier molecule or solid support is labeled with an alkyne or an activated alkyne group;

wherein said reporter molecule, carrier molecule or solid support attaches to the first protein at the azide group of said attached azido-modified galactose through the alkyne or the activated alkyne group, thereby forming the glycomodified protein; and

wherein said attaching of the azido-modified galactose (GalNAz) is carried out by an enzymatic attachment step utilizing a mutant β-1,4-galactosyl transferase enzyme (Y289L GalT1) and UDP-GalNAz as a substrate, which transfers said azido-modified galactose (GaINAz) from said UDP-GalNAz to said GlcNAc residue of said first protein.

2. The method of claim 1 , wherein said first protein is an antibody.

3. The method of claim 1 , wherein prior to the attaching step, the method comprises cleaving an oligosaccharide present on a first protein at a GlcNAc-GlcNAc linkage to obtain a protein comprising a GlcNAc residue.

4. The method of claim 3 , wherein said oligosaccharide is cleaved using endoglycosidase H cleavage at the GlcNAc-GlcNAc linkage.

5. The method of claim 1 , wherein said first protein is derived from a non-human source.

6. The method of claim 5 , wherein said glycomodified protein is humanized.

7. The method of claim 3 , wherein said oligosaccharide is cleaved using endoglycosidase M cleavage at the GlcNAc-GlcNAc linkage.

8. The method of claim 1 , wherein the attaching step is in a solution substantially free of proteases.

9. The method of claim 1 , wherein said reporter molecule is selected from the group consisting of a fluorescent dye, an enzyme, a radiolabel, a metal chelator, and a detectable substrate.

10. The method of claim 1 , wherein said carrier is selected from the group consisting of therapeutic agents, DNA, protein, peptides, and sugars.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO 09452626 PREVIOUSLY RECORDED ON REEL 023882 FRAME 0551. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER SHOULD NOT HAVE BEEN RECORDED AGAINST THIS PATENT APPLICATION NUMBER. Recorded Nov 14, 2014
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 034217/0490 →
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
MERGER Recorded Feb 3, 2010
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023882/0551 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →